Abstract：Objective: To study the therapeutic effect of Fu-ganlin oral liquid on respiratory syncytial virus(RSV) infection in mice. Methods: The 120 ICR mice were randomly divided into 6 groups, which with regular control group, infection model group, Ribavirin group (150 mg/kg), Fu-ganlin oral liquid group 5g/kg, Fu-ganlin oral liquid 10 g/kg group and Fu-ganlin oral liquid 20 g/kg group. These ICR mice were infected by RSV with intranasal infection method to make effective animal models. Then according to the experimental grouping, the treatment of gavage was carried out respectively. And the control group and the infection model group were treated with the same amount of physiological saline, 2 times a day and a total of 6 days . At last, we used HE staining to observe pathological changes in mice by Fuganlin oral liquid treatment after 6 days. In addition, IFN-β, IL-6 content and gene expression level with infected mice in alveolar lavage fluid and lung tissue were analyzed by ELISA and real time fluorescence quantitative PCR methods during the treatment. The peripheral blood was sampled and detected CD3+CD4+ and CD3+CD8+ levels after heparinization with flow cytometer Results: The mouse model of RSV infection was successfully established. The pathological results of HE staining showed that the pathological changes of lung tissue in different treatment groups were improved, and the Fu-ganlin oral liquid 10 g/kg and 20 g/kg groups in the mice were most significantly improved in the lung tissue. The level of IFN-β, IL6 and gene expression of mice lung tissue decreased gradually, and the peripheral blood level of the above inflammation factors in each treatment group was compared with the control group. Among them, The level of CD3+CD4+ in the model group, Ribavirin group and the Fu-ganlin oral liquid 5 g/kg group increased significantly(P<0.05); the CD3+CD4+ of the Fu-ganlin oral liquid 10g/kg and the 20 g/kg group decreased significantly(P<0.05). And the levels of CD3+CD4+/CD3+CD8+ in the model group increased significantly(P<0.05),the Fu-ganlin oral liquid 20 g/kg group were significantly decreased(P<0.05),the levels of CD3+CD4+/CD3+CD8+ in the Ribavirin group, Fu-ganlin oral liquid 5 g/kg and 10 g/kg groups had no significant difference. Conclusion: The treatment group of "Fuganlin oral liquid " has a promising therapeutic effect on RSV infection in mice in a dose-dependent manner. The effect of high dose group is more significant.
收稿日期: 2018-02-07
基金资助:
上海市综合医院中西医结合专项(ZHYY-ZXYJHZX-2-08)；上海儿童医学中心横向课题
通讯作者:
张皓（通讯作者），主任医师，E-mail：scmc_zhang@163.com
作者简介: 张磊(1978—)，男，江苏武进人，硕士，副主任医师，主要从事小儿呼吸内科研究
引用本文:
张磊， 张皓， 殷勇， 张静， 袁姝华， 邬宇芬， 唐铭钰， 吴巾红. 馥感啉口服液对呼吸道合胞病毒感染小鼠的治疗作用[J]. 江苏大学学报:医学版, 2019, 29(05): 398-404.
ZHANG Lei， ZHANG Hao, YIN Yong， ZHANG Jing， YUAN Shu-hua，WU Yu-fen, TANG Ming-jue, WU . The therapeutic effect of Fu-ganlin oral liquid on respiratory syncytial virus infection in mice. Journal of Jiangsu University(Medicine Edition), 2019, 29(05): 398-404.
［1］Herzog B, Gardner DJ, LopezAnido R, et al. The burgeoning burden of respiratory syncytial virus among children\[J\]. Infect Disord Drug Targets, 2012, 12(12):92-97.［2］Hall CB, Simes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus\[J\]. Curr Top Microbiol Immunol, 2013, 372:39-57.［3］Kyeyagalire R, Tempia S, Cohen AL, et al. Hospitalizations associated with influenza and respiratory syncytial virus among patients attending a network of private hospitals in South Africa, 2007—2012\[J\]. BMC Infect Dis, 2014, 14(1):694.［4］Nair H, Nokes DJ,Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis\[J\].Lancet,2010,375(9725):1545-1555.［5］Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations\[J\]. Infect Disord Drug Targets, 2012, 12(2):98-102.［6］Devincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS5806 activity in a respiratory syncytial virus challenge study\[J\]. N Engl J Med, 2014, 371(8):711-722.［7］邢丽辉, 朴春姬, 吴军. 中药馥感啉口服液雾化吸入结合西药治疗婴幼儿病毒性肺炎65例\[J\]. 中国社区医师（综合版）, 2005,7（20）:32.［8］银羽. 馥感啉口服液治疗小儿急性上呼吸道感染疗效观察\[J\]. 中国实用医药, 2013, 8(4):149-150.［9］杨瑞瑞，罗定强，黄艳. HPLC法测定馥感啉口服液中盐酸麻黄碱的含量［J］.安徽医药，2009，13（6）：613-614.［10］王长娟, 李海军, 吴剑华. 馥感啉口服液治疗儿童流行性腮腺炎临床疗效观察\[J\]. 上海医药, 2015,36（19）:21.［11］Wang J， Wu J， Kong L， et al. BuShenYiQi Formula strengthens Th1 response and suppresses Th2Th17 responses in RSVinduced asthma exacerbated mice\[J\]. J Ethnopharmacol,2014,154(1):131-147.［12］Rodriguez WL，Kim HW，Brandt CD，et al. Aerosolized ribavirin in the treatment of Patients with respiratory syncytial virus disease\[J\].Pediatr Infect Dis J, 1987,6(2):159-163.［13］Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options\[J\]. Clinicoecon Outcomes Res, 2014,6:217-225.［14］祁子君.利巴韦林雾化吸入治疗新生儿合胞病毒肺炎的临床分析\[J\]. 中国基层医药, 2009, 16(12): 2250.
2019, Vol. 29 
